LIPID THERAPY FOR NEUROLOGICAL DISEASE

Abstract

Aberrant lipid metabolism in the formation of very long chain fatty acids forming ceramides or lipid rafts may follow exposure to neurotoxins and may be biomarkers of neuroinflammation in patients presenting with ASD (Autistic Spectrum Disorder), Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, post-stroke, Muscular Dystrophy, Guillain-Barre Syndrome, Huntington’s Disease, Niemann Pick Type C, pervasive developmental delay (PDD), neurotoxicity heavy metals, toxic mold, bacteria, virus’, chemicals) and ALS subjects which we have documented in medical presentations and literature from 1996^3,4,5,6,7. Detailed history of exposure of neurotoxins as heavy metals (such as maternal fish consumption), xenobiotics (pesticides), and microbial exposure (fumonisin from com) are carefully evaluated in our subjects along with appropriate laboratory testing. A lipid stabilizing intravenous protocol is introduced to stabilize brain architecture and to address neurotoxic exposure and neuroinflammation.

Our targeted Membrane Stabilizing IV therapy with phosphatidylcholine, Leucovorin, rGlutathione and phenylbutyrate is an attempt to clear neurotoxins, support hepatic function, address cell membrane phospholipid integrity, and stabilize the state of neuroinflammation that may accompany neuroinflammatoiy disorders such as ASD, Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, post-stroke, Guillain-barre Syndrome, Huntington’s Disease, Niemann Pick Type C and ALS subjects. Oral therapy includes highly unsaturated fatty acids (HUF A), 4:1 ratio of omega-6 to omega-3 polyunsaturated fatty acids (PUFA), fatty alcohols, butyrate or Phenylbutyrate, PC and methylation support. Oral targeted treatment regimes are utilized after red cell lipid analysis has been completed at Kennedy Krieger Institute’s Peroxisomal laboratoiy in Baltimore, Maryland and biomedical analysis through BodyBio in Millville, NJ. We have noted marked improvement in regard to neurological function in our combined patient population of 1000. Continued IV and oral lipid therapy yields sustained clinical improvement.